Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.
Actively Recruiting
Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.
Actively Recruiting
Researchers are evaluating the early use of empagliflozin, taken once daily by mouth, in patients hospitalized with acute heart failure who are at high risk of complications. This Phase 3, multicenter, randomized, double-blind trial compares empagliflozin to a placebo to assess its safety and effectiveness. The study is sponsored by Juntendo University and focuses on important outcomes like death, rehospitalization, worsening heart failure, and urine output within 90 days of treatment. Participants will be randomly assigned to receive either empagliflozin 10 mg once daily or a matching placebo. Treatment begins within 12 hours of hospital presentation. Both groups will be closely monitored during hospitalization and for up to 90 days after starting the study drug. The study uses a quadruple-blind design, meaning patients, caregivers, investigators, and assessors do not know which treatment is given. During the study, participants will undergo various assessments including monitoring of heart failure symptoms, urine output, blood tests for heart and kidney function, and quality of life questionnaires. Researchers will measure outcomes such as death rates, heart failure rehospitalizations, symptom changes, and kidney function over 90 days. Safety will be closely tracked throughout the study period. Total participation time varies but includes hospital stay and follow-up visits up to 90 days.
Actively Recruiting
Researchers are evaluating the safety and clinical effects of Awiqli in people with diabetes mellitus in Japan during routine medical care. This observational study aims to collect real-world data on the use of Awiqli over a one-year period. The study focuses on participants with any type of diabetes who are prescribed Awiqli independently of the study. Participants will receive commercially available Awiqli as directed by their treating doctors according to standard clinical practice. There is no experimental treatment assignment as this is a non-interventional study. The study observes the use of Awiqli over 52 weeks without altering usual care. During the study, participants will be monitored for adverse reactions and events, serious adverse events, and changes in diabetes-related clinical parameters including HbA1c, fasting plasma glucose, and diabetes therapy-related quality of life. Data will be collected from baseline through week 52. The total participation time lasts about one year.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a new device called MDT-0123 compared with the autologous iliac bone graft ICBG in patients who need bone fusion using spinal fixation at two levels ALIF or OLIF due to disc degeneration or spinal deformity in the lower spine L2-S1. This study is a prospective, multi-center, randomized trial aiming to stabilize the spine and improve intervertebral support and correction. Participants will receive either the MDT-0123 spine cage combined with the MDT-0123 kit or the MDT-0123 spine cage combined with the iliac bone graft. Treatments involve surgical implantation of these devices for spinal fusion. The trial compares these two approaches to assess their efficacy and safety over time. During the study, participants will be closely monitored through various assessments including imaging scans such as MRI or myelography, evaluations of disc height, general health condition, disability index Oswestry Disability Index, and pain levels in the lower back and legs. The primary outcomes focus on efficacy and safety at 12 months. Bone fusion timing and other secondary measures will also be tracked. Participants will undergo follow-up visits and evaluations during the 12-month period after surgery to monitor progress and measure study outcomes.
Actively Recruiting
Researchers are conducting a survey to monitor the safety and effectiveness of Ondexxya Intravenous Injection 200 mg in patients who have received this treatment. The focus is on understanding the occurrence of specific safety concerns, including thrombotic events, infusion reactions, and re-bleeding, in patients treated for life-threatening bleeding related to Factor Xa inhibitors. The survey gathers information under real-world use conditions to detect any unknown adverse drug reactions, assess the incidence of known adverse effects, and identify factors that may influence the safety or effectiveness of the drug. There are no assigned intervention groups, as this is an observational study collecting data from patients treated with Ondexxya. Participants are monitored for 30 days to evaluate the incidence of adverse drug reactions and safety events related to their treatment. Safety and effectiveness information is collected through routine clinical care without additional interventions. The study will continue until October 31, 2026, with outcomes focused on adverse reactions and safety specifications during the observation period.
Actively Recruiting
Long-Term Safety Study of Nivolumab and Other Cancer Therapies in Patients from BMS-Sponsored Trials
Researchers are examining the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This phase 2 study focuses on patients who have previously participated in Bristol-Myers Squibb-sponsored trials involving nivolumab and other cancer treatments. The goal is to monitor safety outcomes over an extended period while patients continue or resume treatment. Participants receive specified doses of nivolumab alone or in combination with other drugs such as ipilimumab, cabozantinib, trametinib, relatlimab, capecitabine, bevacizumab, temozolomide, and others according to their assigned study group. The study includes multiple experimental arms with different drug combinations and dosing schedules, all delivered as drug treatments. Participants continue treatment based on eligibility from their parent studies, including those who are on treatment hold or eligible for rechallenge. Throughout the study, participants undergo regular safety assessments to monitor adverse events, serious adverse events, immune-mediated effects, and any events leading to treatment discontinuation. Monitoring begins from the first day of treatment and continues up to 135 days after treatment ends. Researchers also track incidences of death during this period. The total participation duration spans from enrollment through ongoing treatment and post-treatment safety follow-up, with data collected to evaluate long-term treatment safety.
Actively Recruiting
Researchers are evaluating whether pemafibrate can help prevent worsening of intracranial arterial stenosis ICAS in people who have symptomatic ICAS and high triglyceride levels after an ischemic stroke or transient ischemic attack TIA. This open-label, randomized, parallel-group trial compares a group receiving pemafibrate with a group not receiving it, while all participants continue standard stroke care including antithrombotic therapy and management of vascular risk factors. The study is sponsored by Tokyo Womens Medical University. Participants assigned to the pemafibrate group will take the drug for 12 months, with possible dose adjustments based on triglyceride levels and kidney function. Both groups will receive standard medical therapy. Brain CT angiography CTA will be performed at the start and after 12 months. Additional assessments include brain MRIMRA and vascular tests such as ankle brachial index, cardio ankle vascular index, and pulse wave velocity, conducted according to the study schedule. During the study, participants will have blood tests and clinical assessments at baseline and follow-up visits. Researchers will monitor vascular events, functional outcomes, and adverse events over 12 months. The main outcome measured is progression of intracranial arterial stenosis on CTA at 12 months. Secondary outcomes include changes in stenosis severity, cardiovascular events, mortality, daily living activities, brain imaging markers, vascular indices, blood biomarkers, and safety measures throughout the treatment period.